Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins
Brief Summary: This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.


Options:
A: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Statin | Arm Label: Alirocumab 75 mg/ Up 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for alirocumab), Drug: Alirocumab, Drug: Statin | Arm Label: Alirocumab 300 mg/ Up 150 mg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for alirocumab), Drug: Alirocumab, Drug: Statin | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W | Intervention Type: DRUG; Name: Statin; Assigned to Arm(s): Alirocumab 300 mg/ Up 150 mg Q4W, Alirocumab 75 mg/ Up 150 mg Q2W, Placebo Q2W
B: Arm Label: Group 1 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 2 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 3 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 4 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 5 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 6 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 7 without atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 8 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Intervention Type: DRUG; Name: REGN727(SAR236553); Assigned to Arm(s): Group 1 with atorvastatin, Group 2 with atorvastatin, Group 3 with atorvastatin, Group 4 with atorvastatin, Group 5 with atorvastatin, Group 6 with atorvastatin, Group 7 without atorvastatin, Group 8 with atorvastatin
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
D: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo

Answer: D